Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 10/20 | 0.57 |
| ▸ | BCL2 | P10415 | 12/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25422653 | 0.90 | BCL2L1 (0.72) | BCL2L1BCL2 | |
| SCHEMBL24483918 | 0.89 | BCL2L1 (0.65) | BCL2L1BCL2GAATP53MAPT | |
| SCHEMBL22325417 | 0.88 | BCL2L1 (0.64) | BCL2L1BCL2GAATP53MAPT | |
| SCHEMBL25711710 | 0.88 | BCL2L1 (0.64) | BCL2L1BCL2GAATP53MAPT | |
| SCHEMBL24483464 | 0.87 | BCL2L1 (0.63) | BCL2L1BCL2GAATP53MAPT | |
| SCHEMBL25713527 | 0.86 | BCL2L1 (0.61) | BCL2L1BCL2GAATP53MAPT | |
| SCHEMBL1567517 | 0.85 | BCL2L1 (0.78) | BCL2L1BCL2GAATP53MAPT | |
| SCHEMBL25423578 | 0.84 | BCL2 (0.59) | BCL2L1BCL2GAATP53MAPT | |
| SCHEMBL15539657 | 0.84 | BCL2L1 (0.64) | BCL2L1BCL2GAATP53MAPT | |
| SCHEMBL22325105 | 0.82 | BCL2L1 (0.63) | BCL2L1BCL2GAATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444717-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | University of Florida Research Foundation, Incorporated (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107606-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20220169628-A1 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-06-02 | — | — | US | disclosed |
| EP-3920923-A2 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | University of Florida Research Foundation, Incorporated (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163823-A2 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169628-A1 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | HDGF, NFATC1, HGF | BCL2L1 317/4885BCL2 6/4885GAA 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.